Basel, Switzerland, June 1, 2026
Roche announced that new clinical data from its obesity portfolio will be presented at the upcoming American Diabetes Association (ADA) 2026 Scientific Sessions, highlighting the continued advancement of its investigational obesity therapies enicepatide (CT-388) and petrelintide. The data underscore Roche’s strategy to address significant unmet needs in obesity management through innovative therapies designed to improve weight loss outcomes, treatment adherence, and patient tolerability. The company believes these assets could play a critical role in expanding personalized treatment options for people living with overweight and obesity.
Enicepatide Demonstrates Strong Potential for Weight Management
Enicepatide (CT-388), Roche’s investigational dual GLP-1/GIP receptor agonist, will be featured in late-breaking Phase II data evaluating weight loss outcomes in adults with overweight or obesity. The therapy is designed to deliver potent receptor activity while minimizing receptor desensitization, potentially enabling sustained efficacy over time. Roche stated that enicepatide has shown encouraging efficacy and safety characteristics that position it as a potential best-in-class obesity treatment. In addition to its standalone potential, the company views enicepatide as a foundational therapy that could support future combination regimens within its growing cardiometabolic portfolio.
Petrelintide Expands Roche’s Next-Generation Obesity Strategy
Petrelintide, an investigational long-acting human amylin analog, will also be highlighted through Phase II ZUPREME-1 trial results demonstrating favorable efficacy, safety, and tolerability in patients with overweight or obesity. The therapy is designed for once-weekly administration and aims to enhance feelings of satiety by activating amylin pathways involved in appetite regulation. Roche believes petrelintide may help redefine the obesity treatment experience by offering meaningful weight management benefits with an attractive tolerability profile. Additional studies are also exploring petrelintide in patients with obesity and type 2 diabetes, further expanding its potential clinical applications.
Advertisement
Roche Advances Combination Approach and Phase III Development
Building on the encouraging clinical findings, Roche plans to advance both enicepatide and petrelintide into Phase III development while launching a new Phase II multi-arm study evaluating fixed-dose combinations of the two agents later in 2026. The company believes combining complementary mechanisms of action could create a differentiated obesity treatment option capable of delivering enhanced efficacy and improved patient outcomes. According to Roche, the latest ADA presentations reinforce the strength of its obesity portfolio and support its long-term strategy to address one of the world’s fastest-growing healthcare challenges through innovative and personalized therapies.
Source: Roche press release
